[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ARCAGY\u002F GINECO GROUP\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,82,110,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642869","phase-1-safety-and-efficacy-of-ubamatamab-with-first-line-chemotherapy-in-ovarian-cancer-100642869",false,"NCT07637851","Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer","A Phase I\u002FII Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy","RegeNovar","Inclusion Criteria:\n\n1. Histologically confirmed high-grade epithelial (serous, endometrioid, or carcinosarcoma with a ≥30% epithelial tumor component) ovarian, primary peritoneal, or fallopian-tube carcinoma\n2. Adult patient aged ≥ 18 years old\n3. Advanced stage III or IV\n4. Treated with 3 or 4 standard neo-adjuvant cycles of carboplatin-paclitaxel regimen, in first line, given every 3 weeks, and characterized by 2 unfavorable features (both are required):\n\n   * A poorly chemosensitive disease defined by an unfavorable standardized KELIM score \\\u003C 1.0 calculated on CA-125 KELIM™ calculator for patients treated with neo-adjuvant chemotherapy\n   * A disease considered not amenable to complete interval cytoreductive surgery with no post-operative macroscopic residual lesion (either because the interval cytoreductive surgery attempt was incomplete CC2-CC3, or because the surgeon considers a complete interval cytoreductive surgery is not achievable based on imaging and\u002For laparoscopic explorations)\n5. Disease measurable and assessable by imaging based on RECIST 1.1 criteria (thorax-abdomen-pelvis CT-scanner; FDG-PET-CT-scanner; and\u002For MRI)\n6. Availability of a tumor tissue for translational research (archival tissue, or alternatively from fresh biopsy, and\u002For surgery)\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n8. BRCA and HRD status known, or planned during the trial (before maintenance treatment)\n9. Adequate bone marrow function\n\n   * Red blood cells: baseline Hemoglobin ≥8 g\u002FdL (without red blood cell transfusion within 3 weeks before the blood work)\n   * White blood cells: Absolute neutrophil count (ANC) ≥1500 cells\u002Fmm3\n   * Platelets: Platelet count ≥100,000\u002Fmm3\n10. Adequate renal and liver functions\n\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases\n    * Total bilirubin ≤1.5 × ULN (patients with Gilbert's are eligible if total bilirubin ≤3 × ULN)\n    * Albumin ≥3 g\u002FdL\n    * Creatinine clearance ≥40 mL\u002Fmin\u002F1.73 m2 (measured or estimated, ideally with CKD-EPI formula on https:\u002F\u002Fwww.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator )\n11. Adequate heart function: LVEF ≥ 50%, measured by echocardiogram, and troponin levels above the upper limit of normal (ULN). The case of troponin level comprised between 1.0 and 2 ULN, inclusion may be discussed after cardiological assessment.\n12. Life expectancy of at least 3 months\n13. Patients who gave their written informed consent to participate to the study\n14. Patients affiliated to a social insurance regime\n15. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up.\n\nNon-inclusion Criteria:\n\n1. Low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.\n2. Patients with primary platinum-refractory disease, defined as disease that has radiologically progressed during the neo-adjuvant chemotherapy\n3. Contraindication to ubamatamab\n4. Contraindication to carboplatin, paclitaxel or bevacizumab\n5. Previous treatment with bevacizumab during initial standard neo-adjuvant chemotherapy\n6. Prior treatment with anti-PD-1 therapies or T-cell therapies, or any other experimental anti-cancer systemic therapy\n7. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years.\n8. All trial participants with brain metastases, except those meeting the following criteria (all criteria are required):\n\n   1. Brain metastases that have been treated locally, and are clinically asymptomatic for at least 4 weeks prior to enrolment,\n   2. No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable).\n   3. Trial participants with brain metastases must be either off steroids except a stable or decreasing dose of \\\u003C10mg daily prednisone (or equivalent).\n9. Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent\n10. Patients receiving any systemic chemotherapy, radiotherapy (except for symptomatic\u002Fpalliative reasons), within 3 weeks before the first dose of ubamatamab. The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study if these were started at least 4 weeks prior to treatment with study drug.\n11. Persistent toxicities (≥CTCAE grade 3), caused by previous cancer therapy\n12. Treatment with other investigational agents.\n13. Bowel occlusive syndrome, inflammatory bowel disease, immune colitis, or other gastro-intestinal disorder that does not allow oral medication, such as malabsorption.\n14. Clinically significant (i.e., active) and severe cardiovascular disease according to investigator opinion such as myocardial infarction (\\\u003C 6 months prior to enrollment); any history of myocarditis; significant arrhythmia including paroxysmal atrial fibrillation requiring intervention at any time or implantation of a pacemaker or defibrillator; signs or symptoms of active angina; arrhythmia or heart failure; LEVF \\\u003C 50% with echocardiogram; QTc (Friedericia) interval \\>470 msec (in cases of asymptomatic prolonged QTc interval (\\>470 msec), the ECG can be repeated up to 2 times. If subsequent QTc interval is \\\u003C470 msec, the patient may be enrolled but only after review and approval by a cardiologist); Evidence of Second-Degree AV block type II (Mobitz type II) or AV block type III (complete heart block); Baseline serum troponin above institutional upper limit of normal. In cases of minimally elevated troponin in absence of clinical symptoms, after clearance by a cardiologist, the patient may be enrolled.\n15. Untreated pulmonary embolism (PE) or deep vein thrombosis (DVT), not currently managed with anticoagulant therapy. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immunological adverse events. The following are not exclusionary: vitiligo, childhood asthma that has resolved, hypothyroidism that required only hormone replacement, type 1 diabetes or psoriasis that does not require systemic treatment\n16. Uncontrolled infection with human immunodeficiency virus, hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency or known latent tuberculosis infection.\n\n    Participants will be tested for HCV and HBV at screening per Section 5.2\n    * Patients with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are permitted.\n    * Patients with hepatitis B surface antigen positive (HepBsAg+) who have controlled infection (serum hepatitis B virus DNA PCR that is below the limit of detection AND receiving antiviral therapy for hepatitis B) are permitted.\n    * Participants with HBsAg negative but total HBV core antibody positive (HBc Ab+) are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, antiviral therapy for HBV must be initiated prior to study entry. If serum HBV DNA PCR is below the limit of detection periodic monitoring of HBsAg must be performed.\n    * Patients who are Hepatitis C virus antibody positive (HCV Ab +) who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.\n17. Other active infections requiring hospitalization or IV anti-infectives within 2 weeks before starting study treatment.\n18. Receipt of a live vaccine within 30 days of planned start of study medication.\n19. Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial.\n20. Women of childbearing potential (WOCBP)\\* who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment, during the study, and for at least 6 months after the last dose. Highly effective contraceptive measures include:\n\n    1. stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening\n    2. intrauterine device (IUD); intrauterine hormone-releasing system (IUS)\n    3. bilateral tubal occlusion\u002Fligation\n    4. vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure) and\u002For e. sexual abstinence\\*\\* \\*\\*\\* \\* WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.\n\n    A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to Clinical Trial Facilitation Group (CTFG) guidance.\n\n    \\*\\* Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.\n\n    \\*\\*\\*Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception. Female condom and male condom should not be used together.\n21. Known psychiatric disorder that would interfere with trial compliance.\n22. Patient deprived of liberty, under guardianship, or under curatorship","FEMALE","18 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are:\n\n* What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab?\n* What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab?\n\nParticipants will:\n\n* Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles.\n* Attend regular clinic visits throughout the treatment period for checkups and tests",[28],"Ovarian Cancer",[30,31,32,33,34],"chemotherapy","poor prognostic","unfavorable primary chemosensitivity","incomplete debulking surgery","KELIM","NOT_YET_RECRUITING","2026-06-04",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":21},"2026-08",{"date":43,"type":21},"2030-04",{"name":45,"class":46},"ARCAGY\u002F GINECO GROUP","OTHER",11,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100335729","phase-2-recurrent-ovarian-carcinosarcoma-anti-pd-1-niraparib-100335729","NCT03651206","Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy","ROCSAN","Inclusion Criteria:\n\n1. Progressive or recurrent uterine carcinosarcoma (Malignant Mixed Mullerian Tumor-MMMT).\n2. The primary diagnosis must be histologically confirmed by pathological expert review of the initial tumor or biopsy at relapse.\n3. Mandatory tumor samples: Availability of an archival FFPE tumor sample(s) from diagnosis, or if not available from relapse setting.\n4. Progressive disease as defined by RECIST 1.1.\n5. Failure after ≥1 prior platinum containing regimen, which may have been given in the adjuvant setting.\n6. Patient must have had 1 prior chemotherapeutic regimen for management of carcinosarcoma that may have included chemotherapy, chemotherapy and radio-chemotherapy, and\u002For consolidation\u002Fmaintenance therapy.\n7. Patient must be free of active infection requiring antibiotics.\n8. Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to beginning protocol treatment; continuation of hormone replacement therapy is permitted.\n9. Patient must have ECOG Performance Status ≤1.\n10. Life expectancy of \\> 2 months.\n11. Adequate bone marrow function:\n\n    * Platelet count greater than or equal to 100,000\u002Fmm3\n    * Absolute neutrophil count (ANC) greater than or equal to 1,500\u002Fmm3\n    * Hemoglobin \\> 9g\u002FdL\n12. Adequate hepatic and renal function:\n\n    * Total bilirubin ≤1.5x Upper Limit of Normal (ULN) unless liver metastases are present, in which case they must be ≤3x ULN (≤2.0 in patients with known Gilberts syndrome OR direct bilirubin ≤ 1 x ULN)\n    * Serum creatinine ≤1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL\u002Fmin using Cockcroft-Gault equation\n    * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN unless liver metastases are present, in which case they must be ≤5x ULN\n    * Alkaline phosphatase \\\u003C 2.5 times ULN\n    * Serum albumin \\> 3 g\u002FdL\n13. International normalized ratio (INR) or prothrombin time (PT) ≤1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) ≤1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.\n14. Patient must have normal BP or adequately treated and controlled hypertension (systolic BP≤140 mmHg and\u002For diastolic BP ≤90 mmHg)\n15. Patient receiving corticosteroids may continue as long as their dose is stable and ≤10mg\u002Fday (prednisone equivalent) for at least 4 weeks prior to initiating protocol therapy.\n16. Patient must agree to not donate blood during the study or for 90 days after the last dose of study treatment.\n17. Patient has a negative urine or serum pregnancy test within 72 hours prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 4 monhs after the last dose of study treatment, or is of nonchildbearing potential.\n\n    * Non-childbearing potential is defined as follows:\n\n      * ≥45 years of age and has not had menses for \\>1 year\n      * Patients who have been amenorrhoeic for \\\u003C2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n      * Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.\n    * For women of childbearing potential: the patient must be willing to use a highly effective contraception measure throughout the study, starting with the screening visit through 4 months after the last dose of study treatment. See Section 4.3. for a list of highly effective contraception methods. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.\n18. Patient must agree to not breastfeed during the study and for 4 months after the last dose of study treatment.\n19. Patient able to take oral medications.\n20. Female aged ≥18 years at time of signing ICF.\n21. Patient must have signed an approved informed consent.\n22. For France only: patient affiliated to, or a beneficiary of, a social security category.\n\nExclusion Criteria:\n\n1. Not enrolled in any interventional clinical trial (except to biological trials that must be validated by the sponsor)\n2. Prior treatment with niraparib or other PARPi therapy or PD1\u002FPDL-1 inhibitors.\n3. Patient has had investigational therapy, immunotherapy, chemotherapy or biological therapy administered within 4 weeks or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to treatment initiation. Patient has had radiotherapy within 4 weeks prior to treatment initiation.\n4. Patients must not have had major surgery ≤ 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects\n5. Patient who has received more than 3 prior cytotoxic chemotherapies for management of uterine carcinosarcoma.\n6. Patient with persistent, clinically significant \\> Grade 1 toxicity.\n7. Patient has clinically significant cardiovascular disease (eg, significant cardiac conduction abnormalities, uncontrolled hypertension, myocardial infarction, uncontrolled cardiac arrhythmia or unstable angina \\\u003C 6 months to enrollment, NYHA grade 2 or greater congestive heart failure, serious cardiac arrhythmia requiring medication, Grade 2 or greater peripheral vascular disease, and history of cerebrovascular accident within 6 months)\n8. Patient with any other severe concurrent disease, which may increase the risk associated with study participation or study drug administration and, in the judgment of the investigator, would make the patient inappropriate for entry into this study, including significant neurologic, psychiatric, infectious, hepatic, renal, or gastrointestinal diseases or laboratory abnormalities. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.\n9. Symptoms or signs of gastrointestinal obstruction requiring parenteral nutrition or hydration or any other gastro-intestinal disorders or abnormalities, including difficulty swallowing, that would interfere with drug absorption.\n10. Patient experienced ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of non-clinically significant lab abnormalities\n11. Participant has had radiation therapy encompassing \\>20% of the bone marrow within 2 weeks prior to Day 1 of protocol therapy or any radiation therapy within 1 week prior to Day 1 of protocol therapy.\n12. Patient has a diagnosis of immunodeficiency or has received systemic steroid therapy \\>10mg\u002Fday (prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy\n13. Participants with known HIV infection are allowed with the following requirements:\n\n    Documented evidence of plasma HIV-1 RNA persistently \\\u003C50 copies\u002FmL ≤3 months prior to AND at Screening. In the \\>3 to 12 months prior to Screening, plasma HIV-1 RNA consistently \\\u003C50 c\u002FmL required; if single increases ≥50 c\u002FmL occurred, they cannot have been persistent nor associated with antiretroviral resistance per investigator assessment AND CD4 cell count \\>350 cells\u002Fmm3 over past 12 months and at Screening (and no measurement ≤350 cells\u002Fmm3 during that time period) AND Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines Participants with history of CDC Stage 3 AIDS-defining disease (CDC, 2014; also known as acquired immunodeficiency syndrome - defining disease) are allowed if AIDS-defining disease has been treated and cured or is stable for ≥3 months prior to study entry. Cutaneous Kaposi's sarcoma not requiring systemic therapy is allowed.\n\n    No history of HIV-associated non-Hodgkin lymphoma ≤5 years prior to study entry.\n\n    No treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening\n14. Patient has known active hepatitis B (e. g., hepatitis B surface antigen \\[HBsAg\\] reactive and HBcAb reactive) or hepatitis C (e.g., hepatitis C virus \\[HCV\\] ribonucleic acid \\[qualitative\\] is detected).\n15. Patient has an active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n16. Patient must not have a history of interstitial lung disease.\n17. Patient has received a live vaccine within 30 days of initiating protocol therapy.\n18. Patient must not have received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating protocol therapy.\n19. Patient must not have received colony-stimulating factors (e.g, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy.\n20. Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n21. Symptomatic CNS metastasis or leptomeningeal carcinomatosis.\n22. Patients with a history of other invasive malignancies (any evidence of other malignancy being present within the last 3 years) or with a concomitant invasive malignancy, with the exception of non-melanoma skin cancer; patients are also ineligible if their previous cancer treatment contraindicates this protocol therapy.\n23. Known hypersensitivity reactions or allergy to investigational drugs or their excipients that contraindicates the subject's participation.\n24. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial.\n25. Patients under psychiatric care and patients admitted to a health or social institution.\n26. Patients deprived of their liberty by judicial or administrative decision.\n27. Patients under a legal protection measure or unable to express their consent.",{"count":57,"type":21},138,[25,59],"PHASE3","Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases\u002F100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \\\u003C 10% and a poor prognosis. After initial treatment (surgery +\u002F- adjuvant radiotherapies +\u002F- chemotherapies (CT)), vast majority of patients relapsed and received diverse CT producing modest benefits, and nearly all patients will die. After first line CT including platinum salt, monotherapy (doxorubicin or paclitaxel) is frequently used for relapsed patients, but the response rate (RR) is \\\u003C20%, progression-free survival (PFS) \\\u003C4 months, and OS \\\u003C1 year. In this unmet need situation, a better knowledge of these aggressive neoplasms is essential to propose new therapeutic options.",[62,63],"Ovarian Carcinosarcoma","Endometrial Carcinosarcoma",[65,66,67,68,69,70,71],"Malignant mixed Mullerian tumors","Metastatic ovarian carcinosarcoma","Recurrent ovarian carcinosarcoma","Metastatic endometrial carcinosarcoma","Recurrent endometrial carcinosarcoma","Niraparib","TSR-042 (Dostarlimab)","RECRUITING","2026-05-28",{"date":75,"type":39},"2026-06-01",{"date":77,"type":39},"2020-07-15",{"date":79,"type":21},"2029-03",{"name":45,"class":46},36,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100453395","phase-2-niraparib-with-bevacizumab-after-complete-cytoreduction-in-patients-with-ovarian-cancer-100453395","NCT05183984","Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer","Randomized Study of Paclitaxel-carboplatin Followed by Niraparib Compared to Paclitaxel-carboplatin-bevacizumab Followed by Niraparib+Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-line Complete Surgery","NIRVANA-1","Inclusion Criteria:\n\nFor inclusion in the study, patient should fulfill the following criteria:\n\n1. Female patient ≥ 18 years of age.\n2. Signed informed consent and ability to comply with treatment and follow-up.\n3. Patient with newly diagnosed, a. Ovarian cancer, primary peritoneal cancer and\u002For fallopian-tube cancer, b. Histologically confirmed (based on local histopathological findings):\n\n   • high grade serous or\n   * high grade endometrioid (grade 2 and 3) or\n   * other epithelial non mucinous and non-clear cell ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation, c. At an advanced stage: FIGO stage IIIA to IIIC of the 2018 FIGO classification.\n4. Patient having undergone frontline, complete cytoreductive surgery (i.e. no visible residual disease): The patient will be considered eligible once the ESGO Quality Assurance in Ovarian Cancer Surgery will have been filled out and validated\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. Patient must have received one cycle of carboplatin AUC 5-6 + paclitaxel 175 mg\u002Fm²\n7. Patient must have started cycle 1 chemotherapy no later than 6 weeks after surgery.\n8. Patient must have a thorax-abdomen-pelvis CT scan between surgery and Cycle 1, with no evidence of disease.\n9. Patient eligible for first line platinum-taxane chemotherapy:\n10. Patient eligible for bevacizumab treatment in combination with chemotherapy and in maintenance. It must be started at the second chemotherapy cycle and be administered at a dose of 15mg\u002Fkg every 3 weeks up to a total of 15 months.\n11. Patient must have normal organ and bone marrow function before first cycle of chemotherapy:\n\n    * Hemoglobin ≥ 9.0 g\u002FdL.\n    * Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL.\n    * Platelet count ≥ 100 x 109\u002FL.\n    * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).\n    * Aspartate aminotransferase\u002FSerum Glutamic Oxaloacetic Transaminase (ASAT\u002FSGOT)) and Alanine aminotransferase \u002FSerum Glutamic Pyruvate Transaminase (ALAT\u002FSGPT)) ≤ 2.5 x ULN.\n    * Serum creatinine ≤ 1. 5 x institutional ULN and GFR \\> 50 mL\u002Fmin, by using an exact measure (ie. Iohexol clearance) or the most appropriate formula (Jeliffe, Cockroft Gault, MDRD, CKD-EPI) to the investigator's discretion.\n    * Patient not receiving anticoagulant medication who has an International Normalized Ratio (INR) ≥1.5 and an Activated ProThrombin Time (aPTT) ≥1.5 x ULN.\n\n    The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or APTT is within therapeutic limits (according to site medical standard). If the patient is on oral anticoagulants, dose has to be stable for at least two weeks at the time of randomization.\n12. Urine dipstick for proteinuria \\\u003C 2+. If urine dipstick is ≥2+, 24-hour proteinuria must be \\\u003C1 g.\n13. Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and\u002For diastolic BP ≤ 90 mmHg).\n14. Formalin fixed paraffin embedded (FFPE) tumor sample from the primary cancer must be available for local BRCA testing and if possible HRD testing (optional).\n15. For countries where this will apply to: a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of a social security category.\n\nExclusion Criteria:\n\n* 1\\. Patient with clear cell adenocarcinoma or carcinosarcoma, non-epithelial origin of the ovarian tumor, the fallopian tube or the peritoneal tumor (i.e. germ cell tumors).\n\n  2\\. Ovarian tumor of low malignant potential (e.g. borderline tumor), or mucinous carcinoma.\n\n  3\\. Patient with a diagnosis, detection, or treatment of another type of cancer ≤ 3 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer in situ that has been definitively treated and synchronous grade 1 stage 1 endometrial cancer) Patient with history of primary triple negative breast cancer may be eligible provided she completed her definitive anticancer treatment more than 3 years ago and she remains breast cancer disease free prior to start of study treatment.\n\n  4\\. Patient with synchronous high grade serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium is not eligible.\n\n  5\\. Patient with myelodysplastic syndrome\u002Facute myeloid leukemia history. 6. Patient receiving radiotherapy within 6 weeks prior to study treatment. 7. Previous allogenic bone marrow transplant. 8. Any previous treatment with PARP inhibitor. 9. Administration of other simultaneous chemotherapy drugs - except during a HIPEC procedure with cisplatin at PDS, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted as are steroid antiemetics).\n\n  10\\. Current or recent (within 10 days prior to randomization) chronic use of aspirin \\> 325 mg\u002Fday.\n\n  11\\. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.\n\n  12\\. Clinically significant (e.g. active) cardiovascular disease, including:\n  * Myocardial infarction or unstable angina within ≤ 6 months of randomization,\n  * New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF),\n  * Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG.\n  * Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living \\[ADL\\] requiring repair or revision).\n\n    13\\. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA), Sub- Arachnoids Hemorrhage (SAH) or Posterior Reversible Encephalopathy Syndrome (PRES).\n\n    14\\. History or evidence of hemorrhagic disorders. 15. Evidence of bleeding diathesis or significant coagulopathy (in the absence of coagulation).\n\n    16\\. History or clinical suspicion of brain metastases or spinal cord compression. CT\u002FMRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression.\n\n    17\\. History or evidence upon neurological examination of central nervous system (CNS) disease, unless adequately treated with standard medical therapy (e.g. uncontrolled seizures).\n\n    18\\. Significant traumatic injury during 4 weeks prior to randomization. 19. Non-healing wound, active ulcer, or bone fracture. Patient with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection is eligible but require 3 weekly wound examinations.\n\n    20\\. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.\n\n    21\\. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.\n\n    22\\. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.\n\n    23\\. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.\n\n    24\\. Pregnant or lactating women. 25. Participation in another clinical study with any intravenous or oral investigational product is not allowed. However, participation in a surgical clinical study including Hyperthermic Chemotherapy (HIPEC) during the surgical procedure is allowed.\n\n    26\\. Patient unable to swallow orally administered medication and patient with gastrointestinal disorders likely to interfere with absorption of the study medication.\n\n    27\\. Patient with a known contraindication or uncontrolled hypersensitivity to the components of paclitaxel, carboplatin, niraparib, bevacizumab, or their excipients.\n\n    28\\. Immunocompromised patient, e.g., with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids or patient who is known to be serologically positive for human immunodeficiency virus (HIV).\n\n    29\\. Participant has a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.","99 Years",{"count":92,"type":21},390,[25],"Randomized, open label, phase II multicenter study to assess the efficacy niraparib versus niraparib +bevacizumab maintenance in patients with newly diagnosed stage IIIA\u002FB\u002FC high-grade epithelial ovarian cancer with no residual disease after frontline surgery and treatment by adjuvant platinum-basedchemotherapy +\u002F-bevacizumab.",[28],[97,98,99,100],"ovarian cancer","frontline surgery","brca status","maintenance","2026-04-08",{"date":103,"type":39},"2026-04-13",{"date":105,"type":39},"2022-02-01",{"date":107,"type":21},"2032-02-01",{"name":45,"class":46},88,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100552676","phase-3-utility-of-adjusting-chemotherapy-dose--dosing-schedule-with-the-salvage-weekly-dose-dense-regimen-in-patients-with-poor-prognostic-ovarian-cancers-based-on-the-tumor-unfavorable-primary-chemosensitivity-and-incomplete-debulking-surgery-100552676","NCT06476184","Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery","A Pragmatic Randomized Phase III Trial to Assess the Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery","SALVOVAR","Inclusion Criteria:\n\n1. Histologically confirmed high-grade epithelial (serous, endometrioid, or carcinosarcoma with a ≥30% epithelial tumor component) ovarian, primary peritoneal, or fallopian-tube carcinoma\n2. Adult patient aged ≥ 18 years old\n3. Advanced stage III or IV disease\n4. Treated with 3 to 4 neo-adjuvant cycles of standard 3-weekly carboplatin-paclitaxel regimen in first-line setting, and characterized by:\n\n   * Unfavorable standardized KELIMTM score \\\u003C 1.0 calculated with the KELIMTM academic tool and available for free on internet site (https:\u002F\u002Fwww.biomarker-kinetics.org\u002FCA-125-neo) (poor primary chemosensitivity)\n   * Not amenable to complete interval debulking surgery (incomplete interval debulking surgery attempt, or disease not operated at all because considered not amenable to complete surgery by surgeon) Of note, a pre-screening inclusion before the start of neo-adjuvant chemotherapy is encouraged as a way of prospectively assessing the CA-125 longitudinal kinetics and surgery evaluation, and subsequently selecting the patients for the randomization sequence\n5. ECOG performance status 0 or 1 (see appendix 2)\n6. Adequate organ and bone marrow function for weekly-dense chemotherapy: red blood cells (baseline Hemoglobin ≥8 g\u002FdL without red blood cell transfusion within 3 weeks before the blood work), white blood cells (Absolute neutrophil count (ANC) ≥1500 cells\u002Fmm3) and platelets (Platelet count ≥100,000\u002Fmm3),\n7. Adequate renal and liver functions\n\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases\n   * Total bilirubin ≤1.5 × ULN (patients with Gilbert's are eligible if total bilirubin ≤3 × ULN)\n   * Albumin ≥3 g\u002FdL\n   * Creatinine clearance ≥40 mL\u002Fmin\u002F1.73 m2 (measured or estimated, ideally with CKD-EPI formula on https:\u002F\u002Fwww.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator)\n8. Patients who gave its written informed consent to participate to the study\n9. Patients affiliated to a social insurance regime\n10. Patients willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up\n\nExclusion Criteria:\n\n1. Low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor. Contraindication to the drugs assessed in the SALVOVAR trial (carboplatin, paclitaxel, GCSF)\n2. Previous treatment with bevacizumab during initial standard neo-adjuvant chemotherapy\n3. Has primary platinum-refractory disease, defined as disease that has progressed during the neo-adjuvant chemotherapy\n4. Patients with concomitant cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥ 5 years\n5. Treatment with other investigational agents in clinical trials.\n6. Clinically significant uncontrolled condition(s) which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation, including but not limited to:\n\n   * Unstable angina.\n   * Myocardial infarction within 6 months of first dose.\n   * Uncontrolled and\u002For severe concomitant diseases (uncontrolled hypertension, ≥ Grade 3 (per CTCAE v5.0) arrhythmia, heart failure, cirrhosis).\n   * Active infectious disease requiring IV therapy (bacteria, viruses) within 2 weeks of first dose.\n   * Gastric-outlet obstruction.\n   * Small bowel obstruction (SBO) defined as computed tomography (CT) scan showing: Dilated loops of small bowel ≤12 weeks of study entry, symptomatic ascites\u002Feffusions requiring paracentesis or thoracentesis ≤30 days of study entry.\n7. Known psychiatric disorder that would interfere with trial compliance.\n8. Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial.\n9. Patient deprived of liberty, under guardianship, or under curatorship.",{"count":119,"type":21},250,[59],"SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the continuation of the standard regimen.",[28],[30,31,32,33,34],"2025-11-28",{"date":126,"type":39},"2025-12-05",{"date":128,"type":39},"2024-07-30",{"date":130,"type":21},"2028-12",{"name":45,"class":46},72,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100408738","phase-2-addition-of-pembrolizumab-to-the-standard-of-care-chemotherapy-in-patient-with-sccoht-100408738","NCT04602377","Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT","Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type","PembroSCCOHT","Inclusion Criteria:\n\n1. Patient who are at least 12 years of age on the day of signing informed consent with previously untreated, pathologically confirmed Small cell carcinoma of the ovary.Patients could be included after one cycle of chemotherapy but have to start treatment within 4 weeks after the first cycle of chemotherapy. They will start the scheme at cycle 2.\n2. Stage FIGO I to IV classification\n3. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n4. Have adequate organ function:\n\n   * Adequate marrow function\n\n     * White blood cell (WBC) \\>2000\u002Fmm3 (stable off any growth factor within 4 weeks of first study drug administration)\n     * Neutrophils \\>1500\u002F mm3 (stable off any growth factor within 4 weeks of first study drug administration)\n     * Platelets \\> 100 × 103\u002Fmm3 (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration)\n     * Haemoglobin \\> 9 g\u002FdL (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration)\n   * Adequate other organ functions\n\n     * ALT and AST \\\u003C 3× institutional ULN\n     * Total bilirubin \\\u003C 1.5× institutional ULN (except Gilbert Syndrome: \\\u003C 3.0 mg\u002FdL)\n     * Normal thyroid function, subclinical hypothyroidism (thyroid-stimulating hormone \\[TSH\\] \\\u003C 10 mIU\u002FmL) or have controlled hypothyroidism on appropriate thyroid supplementation\n     * Left ventricular ejection fraction (LVEF) \\> 55 % measured by ECHO (preferred) or MUGA scans\n     * Serum creatinine \\\u003C 2× ULN or creatinine clearance (CrCl) \\> 60 mL\u002Fmin (measured using the Cockcroft-Gault formula below):\n5. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial, prior to any study-specific procedure. The participant may also provide consent for (140 - age in years) × weight in kg × 0.85 Female CrCl = 72 × serum creatinine in mg\u002FdL GINECO-OV243b - PembroSCCOHT - Protocol - Version 1.2 - 10\u002F09\u002F2020 Page 7 sur 83 Future Biomedical Research. However, participant may participate in the main trial without participating in Future Biomedical Research.\n6. Covered by a medical insurance\n7. Stated willingness to comply with all study procedures and availability for the duration of the study\n8. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to treatment allocation\n9. For females of reproductive potential: use of highly effective contraception throughout the study period up to 120 days after the last dose of pembrolizumab and 180 days following the end of chemoradiotherapy (if applicable).\n\nExclusion Criteria:\n\n1. Prior therapy for the disease with chemotherapy and\u002For an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).\n2. Patients who have received a live vaccine within 30 days prior to the first dose of study drug.\n\n   Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Inactivated rabies vaccines are allowed.\n3. Patients who have had an allogenic tissue\u002Fsolid organ transplant.\n4. Patient who has received more than one cycle of platinum-based chemotherapy, or any prior systemic anti-cancer therapy including investigational agents for the SCCOHT. (Patients could be included after one cycle of platinum-based therapy).\n5. Patients who have a known diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.\n6. Patients who have a known additional malignancy that is progressing or has required active treatment within the past 5 years.\n\n   Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.\n7. Patients who have a contraindication to any component of cisplatin, adriamycine, vepeside and cyclophosphamide.\n\n   Note: Investigators must use the local label for contraindications, prohibited medications, and precautions for use.\n8. Patients who have severe hypersensitivity (Grade 3 or higher) to pembrolizumab and\u002For any of its excipients (refer to the IB for a list of excipients).\n9. Patients who have a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and\u002For to any of their excipients (refer to the approved product label(s) for a list of excipients).\n10. Patients who have an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n11. Patients who have a history of (non-infectious) pneumonitis\u002F interstitial lung disease that required steroids or has current pneumonitis \u002F interstitial lung disease that requires steroids.\n12. Has an active infection requiring systemic therapy.\n13. Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.\n14. Has a history of hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or active hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection.\n15. Has a known history of active tuberculosis (TB; Bacillus tuberculosis)\n16. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n17. Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.\n18. Breastfeeding women\n19. Participation in another clinical study with an investigational product 30 days prior and during the treatment course, and 30 days after end of treatment.","12 Years",{"count":143,"type":21},27,[25],"Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to offer to more patients the possibility of benefiting from an intensification of chemotherapy, which is a major prognostic factor in this population.",[147],"Small Cell Ovarian Carcinoma","2025-11-24",{"date":124,"type":39},{"date":151,"type":39},"2021-08-04",{"date":153,"type":21},"2030-02",{"name":45,"class":46},13,""]